keyboard_arrow_up

Global Pancreatic Cancer Market to Grow at 10.70% CAGR to 2018

Sandlerresearch.org adds Global Pancreatic Cancer Market 2014-2018 in its store. One major trend in the market is the use of combination therapies, which use multiple mechanisms for the treatment of cancer; hence, are generally more efficacious than monotherapies.

According to the “Global Pancreatic Cancer Market 2014-2018” report, lack of safe, efficacious, and cost-effective treatment is a huge unmet need that is driving market growth. Any drug that would cater to these demands is expected to drive the market during the forecast period.

The report recognizes the following companies as the key players in the Global Pancreatic Cancer Market: Celgene Corp., Eli Lilly and Co., F. Hoffmann-La Roche Ltd., Novartis AG and Pfizer Inc.

Other Prominent Vendors in the market are: AbGenomics International, AB Science, Aduro Biotech, Aphios, Celsion, Gilead Sciences, Halozyme Therapeutics, Merrimack Pharmaceuticals, Momenta Pharmaceuticals, OncoMed Pharmaceuticals, Oncozyme Pharma, Ostuka Holdings, Rexahn Pharmaceuticas and Zeria Pharmaceutical.

Further, the report states that poor diagnosis rate is one of the major challenges in the market. Pancreatic cancer is usually detected during advanced stages of the disease. This, in turn, delays the time of initiation of therapy and decreases survival chances.

Order a copy of this report at (Prices start at US $2500 for a single user PDF) http://www.sandlerresearch.org/purchase?rname=25175.

List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Global Pancreatic Cancer Market 2013-2018 (US$ million)
Exhibit 3: Global Pancreatic Cancer Market Segmentation by Type of Therapy
Exhibit 4: Global Pancreatic Cancer Market Segmentation by Geography 2013
Exhibit 5: Pancreatic Cancer Market in the US 2013-2018 (US$ million)
Exhibit 6: Pancreatic Cancer Market in the 5EU 2013-2018 (US$ million)
Exhibit 7: Regulatory Approval Timeline of Abraxane in the US
Exhibit 8: Regulatory Approval Timeline of Abraxane in the EU
Exhibit 9: Regulatory Approval and Revenue Trend of Abraxane
Exhibit 10: Quarterly Sales of Abraxane Segmented by Geography 2010-2014 (US$ million)
Exhibit 11: Quarterly Sales of Abraxane Segmented by Geography 2010-2014
Exhibit 12: Market Revenue of Abraxane 2010-2014 (US$ million)
Exhibit 13: Regulatory Approval Timeline of Afinitor in the US
Exhibit 14: Regulatory Approval Timeline of Afinitor in the EU
Exhibit 15: Regulatory Approval and Revenue Trend of Afinitor
Exhibit 16: Market Revenue of Afinitor 2008-2014 (US$ million)
Exhibit 17: Quarterly Sales of Afinitor 2011-2014 (US$ million)
Exhibit 18: Quarterly Sales of Afinitor Segmented by Geography 2012-2014 (US$ million)
Exhibit 19: Quarterly Sales Trend of Afinitor Segmented by Geography 2012-2014 (US$ million)
Exhibit 20: Regulatory Approval Timeline of Tarceva in the US
Exhibit 21: Regulatory Approval Timeline of Tarceva in the EU
Exhibit 22: Regulatory Approval and Revenue Trend of Tarceva
Exhibit 23: Market Revenue of Tarceva 2004-2014 (US$ million)
Exhibit 24: Quarterly Sales of Tarceva Segmented by Geography 2004-2008 (US$ million)
Exhibit 25: Quarterly Sales of Tarceva Segmented by Geography 2009-2014 (US$ million)
Exhibit 26: Regulatory Approval Timeline of Gemzar in the US
Exhibit 27: Regulatory Approval and Revenue Trend of Gemzar
Exhibit 28: Market Revenue of Gemzar 1996-2011 (US$ million)
Exhibit 29: Regulatory Approval Timeline of Sutent in the US
Exhibit 30: Regulatory Approval Timeline of Sutent in the EU
Exhibit 31: Regulatory Approval and Revenue Trend of Sutent
Exhibit 32: Market Revenue of Sutent 2007-2014 (US$ million)
Exhibit 33: Quarterly Sales of Sutent Segmented by Geography 2007-2014 (US$ million)
Exhibit 34: Quarterly Sales of Sutent in International Markets 2010-2014 (US$ million)
Exhibit 35: Celgene Corp.: Business Segmentation by Revenue 2011-2013 (US$ million)
Exhibit 36: Celgene Corp.: Sales by Geography 2013
Exhibit 37: Eli Lilly and Co.: Business Segmentation by Revenue 2013
Exhibit 38: Eli Lilly and Co.: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 39: Eli Lilly and Co.: Sales by Geography 2013
Exhibit 40: F. Hoffmann-La Roche: Business Segmentation by Revenue 2013
Exhibit 41: F. Hoffmann-La Roche: Business Segmentation by Revenue 2012 and 2013
Exhibit 42: F. Hoffmann-La Roche: Geographical Segmentation by Revenue 2013 (Pharmaceuticals Division)
Exhibit 43: F. Hoffmann-La Roche: Geographical Segmentation by Revenue 2013 (Diagnostics Division)
Exhibit 44: Novartis AG: Business Segmentation by Revenue 2013
Exhibit 45: Novartis AG: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 46: Novartis AG: Sales by Geography 2013
Exhibit 47: Pfizer Inc.: Business Segmentation
Exhibit 48: Pfizer Inc.: Revenue by Business Segmentation 2013
Exhibit 49: Pfizer Inc.: Revenue by Business Segmentation 2012 and 2013
Exhibit 50: Pfizer Inc.: Revenue by Geography 2013

Have any questions on the report please contact us @ http://www.sandlerresearch.org/inquire-before-buying?rname=25175.

About US

Sandlerresearch.org is an online market research store for research reports on multiple industries. These reports provide market analysis, trends and opportunities and forecast about industries that helps to make a right decision for the business.